UA118759C2 - Сполуки 3,4-дигідроізохінолін-2(1н)-ілу - Google Patents

Сполуки 3,4-дигідроізохінолін-2(1н)-ілу

Info

Publication number
UA118759C2
UA118759C2 UAA201511029A UAA201511029A UA118759C2 UA 118759 C2 UA118759 C2 UA 118759C2 UA A201511029 A UAA201511029 A UA A201511029A UA A201511029 A UAA201511029 A UA A201511029A UA 118759 C2 UA118759 C2 UA 118759C2
Authority
UA
Ukraine
Prior art keywords
compounds
dihydroisoquinolin
formula
schizophrenia
parkinson
Prior art date
Application number
UAA201511029A
Other languages
English (en)
Inventor
Крістофер Дейвід Бідл
Дейвід Ендрю Коутс
Цзюньлян Хао
мол. Джозеф Херман Крушински
Метью Роберт Рейнхард
Джон Менерт Шаус
Крейг Даніел Вулфейнджел
Original Assignee
Елі Ліллі Енд Компані
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Елі Ліллі Енд Компані filed Critical Елі Ліллі Енд Компані
Publication of UA118759C2 publication Critical patent/UA118759C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Цим винаходом запропоновані певні сполуки 3,4-дигідроізохінолін-2(1Н)-ілу, зокрема сполуки формули (І), і фармацевтичні композиції на їх основі. Крім того, цим винаходом запропоновані способи застосування сполуки формули (І) для лікування когнітивних порушень, пов'язаних з хворобою Паркінсона або шизофренією. EMBED ISISServer І
UAA201511029A 2013-05-30 2014-05-27 Сполуки 3,4-дигідроізохінолін-2(1н)-ілу UA118759C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361828740P 2013-05-30 2013-05-30
US201361905329P 2013-11-18 2013-11-18
PCT/US2014/039494 WO2014193781A1 (en) 2013-05-30 2014-05-27 3,4-dihydroisoquinolin-2(1h)-yl compounds

Publications (1)

Publication Number Publication Date
UA118759C2 true UA118759C2 (uk) 2019-03-11

Family

ID=50983199

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201511029A UA118759C2 (uk) 2013-05-30 2014-05-27 Сполуки 3,4-дигідроізохінолін-2(1н)-ілу

Country Status (38)

Country Link
US (1) US8962654B2 (uk)
EP (1) EP3004061B8 (uk)
JP (2) JP6130590B2 (uk)
KR (1) KR101808933B1 (uk)
CN (1) CN105228985B (uk)
AP (1) AP2015008867A0 (uk)
AU (2) AU2014274435B2 (uk)
BR (1) BR112015029090B1 (uk)
CA (1) CA2912849C (uk)
CL (1) CL2015003444A1 (uk)
CR (1) CR20150622A (uk)
CY (1) CY1119361T1 (uk)
DK (1) DK3004061T3 (uk)
DO (1) DOP2015000289A (uk)
EA (1) EA029220B1 (uk)
ES (1) ES2647086T3 (uk)
GT (1) GT201500334A (uk)
HK (1) HK1216314A1 (uk)
HR (1) HRP20171696T1 (uk)
HU (1) HUE034607T2 (uk)
JO (1) JO3316B1 (uk)
LT (1) LT3004061T (uk)
ME (1) ME02838B (uk)
MX (1) MX2015016495A (uk)
MY (1) MY180751A (uk)
NZ (1) NZ713809A (uk)
PE (1) PE20152032A1 (uk)
PH (1) PH12015502658B1 (uk)
PL (1) PL3004061T3 (uk)
PT (1) PT3004061T (uk)
RS (1) RS56294B1 (uk)
SG (1) SG11201509310QA (uk)
SI (1) SI3004061T1 (uk)
TN (1) TN2015000514A1 (uk)
TW (2) TWI691489B (uk)
UA (1) UA118759C2 (uk)
WO (1) WO2014193781A1 (uk)
ZA (1) ZA201508213B (uk)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010324810B2 (en) 2009-11-27 2016-05-12 Genzyme Corporation An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
JO3316B1 (ar) * 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
AR106332A1 (es) * 2015-10-23 2018-01-03 Lilly Co Eli Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona
CA3018352A1 (en) * 2016-04-13 2017-10-19 Ucb Biopharma Sprl Tetrahydroisoquinoline derivatives
AU2018225556A1 (en) 2017-02-21 2019-10-03 Emory University Chemokine CXCR4 receptor modulators and uses related thereto
EP3418270A1 (en) 2017-06-19 2018-12-26 Universidad Complutense De Madrid Novel biphenylsulfoximines as allosteric modulators of the dopamine d1 receptor
EP3717025B1 (en) 2017-12-01 2021-11-03 UCB Biopharma SRL Imaging agents
TWI725408B (zh) 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑
AU2019402087B2 (en) 2018-12-18 2023-04-06 Eli Lilly And Company Dose regimens for use of LY3154207 in the treatment of dopaminergic CNS disorders
TWI825323B (zh) * 2019-06-18 2023-12-11 美商美國禮來大藥廠 用於製備2-(2,6-二氯苯基)-1-[(1s,3r)-3-(羥甲基)-5-(3-羥基-3-甲基丁基)-1-甲基-3,4-二氫異喹啉-2(1h)-基]乙烯酮之方法及中間物
WO2021001286A1 (en) 2019-07-01 2021-01-07 UCB Biopharma SRL A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
MX2021015873A (es) 2019-07-01 2022-02-03 UCB Biopharma SRL Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1.
WO2022076418A1 (en) 2020-10-07 2022-04-14 Eli Lilly And Company Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1 receptor positive allosteric modulators
CN116507332A (zh) 2020-12-03 2023-07-28 Ucb生物制药有限责任公司 八氢异喹啉基衍生物
MX2023007155A (es) 2020-12-18 2023-06-28 UCB Biopharma SRL Un derivado de tetrahidroisoquinolina sustituido como un modulador alosterico positivo de d1.
US20240083875A1 (en) * 2020-12-18 2024-03-14 UCB Biopharma SRL Dihydroisoquinolinyl derivatives
IL303688A (en) * 2020-12-18 2023-08-01 UCB Biopharma SRL Amorphous solid dispersions
US20240083925A1 (en) * 2020-12-18 2024-03-14 UCB Biopharma SRL Prodrugs of 2-(3,5-Dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone
BR112023018175A2 (pt) 2021-03-08 2023-10-31 Lilly Co Eli Uso de mevidalen e outros moduladores alostéricos d1 positivos no tratamento de alucinações e psicose relacionada à demência
WO2022192255A1 (en) 2021-03-09 2022-09-15 Eli Lilly And Company Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE97893T1 (de) 1988-02-19 1993-12-15 Smithkline Beecham Farma 1,2,3,4-tetrahydroisoquinoline, verfharen zu ihrer herstellung und ihre verwendung als kappa- rezeptor agonisten.
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5236934A (en) * 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
US5932590A (en) 1996-12-05 1999-08-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
HUP0101280A3 (en) 1998-02-18 2003-02-28 Neurosearch As Positive ampa receptor modulator compounds and their use
AU5959201A (en) 2000-05-11 2001-11-20 Bristol Myers Squibb Co Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
US7601739B2 (en) 2003-08-08 2009-10-13 Virgina Commonwealth University Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases
US7541466B2 (en) 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
US20090099158A1 (en) 2007-03-01 2009-04-16 Grice Cheryl A Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor
US20120252853A1 (en) * 2011-04-01 2012-10-04 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
KR20140107550A (ko) 2011-12-21 2014-09-04 액테리온 파마슈티칼 리미티드 헤테로시클릴 유도체 및 프로스타글란딘 ｄ2 수용체 조절제로서의 그의 용도
JO3316B1 (ar) * 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل

Also Published As

Publication number Publication date
US20140357664A1 (en) 2014-12-04
MY180751A (en) 2020-12-08
BR112015029090A2 (pt) 2017-07-25
KR20160003110A (ko) 2016-01-08
ZA201508213B (en) 2017-08-30
NZ713809A (en) 2019-11-29
CN105228985A (zh) 2016-01-06
TWI691488B (zh) 2020-04-21
MX2015016495A (es) 2016-03-01
CR20150622A (es) 2016-01-06
BR112015029090A8 (pt) 2020-03-17
US8962654B2 (en) 2015-02-24
CY1119361T1 (el) 2018-02-14
CA2912849A1 (en) 2014-12-04
AU2016238934A1 (en) 2016-10-27
DK3004061T3 (en) 2017-10-23
ME02838B (me) 2018-01-20
PL3004061T3 (pl) 2018-01-31
PH12015502658A1 (en) 2016-03-07
JP6130590B2 (ja) 2017-05-17
KR101808933B1 (ko) 2017-12-13
TW201536745A (zh) 2015-10-01
PT3004061T (pt) 2017-10-19
SG11201509310QA (en) 2015-12-30
EA201592082A1 (ru) 2016-04-29
HRP20171696T1 (hr) 2017-12-29
SI3004061T1 (sl) 2017-10-30
EA029220B1 (ru) 2018-02-28
EP3004061B8 (en) 2017-10-04
HUE034607T2 (en) 2018-02-28
CN105228985B (zh) 2017-05-10
TW201940469A (zh) 2019-10-16
AU2016238934B2 (en) 2017-08-03
JP2016520127A (ja) 2016-07-11
LT3004061T (lt) 2017-11-27
PH12015502658B1 (en) 2016-03-07
CA2912849C (en) 2017-05-30
EP3004061A1 (en) 2016-04-13
JP6387433B2 (ja) 2018-09-05
TN2015000514A1 (en) 2017-04-06
CL2015003444A1 (es) 2016-07-15
AU2014274435B2 (en) 2016-07-14
BR112015029090B1 (pt) 2023-05-09
JP2017178945A (ja) 2017-10-05
AU2014274435A1 (en) 2015-11-19
DOP2015000289A (es) 2015-12-31
PE20152032A1 (es) 2016-01-28
TWI691489B (zh) 2020-04-21
WO2014193781A1 (en) 2014-12-04
JO3316B1 (ar) 2019-03-13
EP3004061B1 (en) 2017-08-30
ES2647086T3 (es) 2017-12-19
GT201500334A (es) 2018-11-23
RS56294B1 (sr) 2017-12-29
HK1216314A1 (zh) 2016-11-04
AP2015008867A0 (en) 2015-11-30

Similar Documents

Publication Publication Date Title
PH12015502658A1 (en) 3,4-dihydroisoquinolin-2 (1h)-yl compounds
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
IN2015DN01156A (uk)
PH12016501192B1 (en) Tetrahydropyridopyrazines modulators of gpr6
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
PH12015502502A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
PH12018501227A1 (en) Drug for preventing and/or treating polycystic kidney disease
MX366308B (es) Derivados de amida como bloqueadores de ttx-s.
GEP20196961B (en) 4-oxo-3,4-dihydro-1,2,3 -benzotriazines modulators of gpr139
PH12016501863A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
MA39914A (fr) Composés hétéroaromatiques et leur utilisation comme ligands de la dopamine d1
MX369451B (es) Formas cristalinas de compuestos basados en 1, 8- naftiridin-4(h)-ona particulares y su uso en el tratamiento de ansiedad y condiciones relacionadas.
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
BR112015006220A2 (pt) agentes antibacterianos de tetrahidroquinolina tricíclica
MA38636A1 (fr) Composés de 3,4-dihydroisoquinoléin-2(1h)-yle
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.
IN2013MU03838A (uk)